Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Nov;13(12):2166-72.
doi: 10.1016/j.cgh.2015.07.015. Epub 2015 Jul 17.

Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients?

Andrew J Muir  1 , Susanna Naggie  2
Affiliations
Review

Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients?

Andrew J Muir et al. Clin Gastroenterol Hepatol. 2015 Nov.

Abstract

The recent advances in hepatitis C virus (HCV) therapeutics have brought combinations of direct acting antiviral medications that offer interferon-free, well-tolerated regimens with sustained virologic response rates greater than 90% in clinical trials for many patient groups. The successes have prompted discussions regarding cure for all patients. These regimens have already demonstrated the ability to cure previously challenging patient groups, including human immunodeficiency virus-HCV coinfection, decompensated cirrhosis, and post-liver transplantation. Limitations exist in the current portfolio of agents, with suboptimal outcomes for genotype 3 and limited data in genotypes 5 and 6. More data are urgently needed in patients with chronic kidney disease and in children. With ongoing developments, highly effective regimens for all these patient groups are within reach. To deliver HCV treatment throughout the world and particularly in low- and middle-income countries, regimens need to be affordable but also pan-genotypic, well-tolerated, and delivered once daily for 4-8 weeks. With such a regimen, cure for all patients would then hinge on the ability to identify patients with HCV infection and deliver treatment within their communities. This review will discuss the strategies that will be necessary to realize this opportunity to cure all persons with HCV infection.

Keywords: Antiviral Agents; Diagnosis; Disease Management; Hepatitis C.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

The authors disclose the following: Dr Muir has received research funding from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc, Janssen Therapeutics, Merck & Co, Inc, Roche, and Vertex Pharmaceuticals and has served as a scientific advisor to AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc, Janssen Therapeutics, Merck & Co, Inc, and Theravance. Dr Naggie has received research funding from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc, Janssen Therapeutics, and Vertex Pharmaceuticals, Inc and has served as a scientific advisor to AbbVie, Bristol-Myers Squibb, Merck & Co Inc, and Gilead Sciences, Inc.

Figures

Figure 1
Figure 1
Characteristics of a HCV regimen that would facilitate wide-scale care.
Figure 2
Figure 2
Estimates of diagnosis and treatment rates of hepatitis C in the United States.
See this image and copyright information in PMC

Comment in

References

    1. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–1887. - PubMed
    1. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211–221. - PubMed
    1. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973–1982. - PubMed
    1. Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014;371:2375–2382. - PubMed
    1. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149:649–659. - PubMed

Substances